Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory Hodgkin's Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT01290549
What this trial is testing

Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma

Who this might be right for
Non-Hodgkins LymphomaChronic Lymphocytic Leukemia
Genentech, Inc. 95
Testing effectiveness (Phase 2)UnknownNCT00014664
What this trial is testing

Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
PDL BioPharma, Inc.
Not applicableEnded earlyNCT00879528
What this trial is testing

Consolidation PET-based and Donor-based After Salvage Therapy in Patients With HL in Relapse or Refractory

Who this might be right for
Hodgkin's Lymphoma
Fondazione Italiana Linfomi - ETS 264
Testing effectiveness (Phase 2)Ended earlyNCT04082936
What this trial is testing

Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

Who this might be right for
Non-Hodgkin LymphomaFollicular LymphomaDLBCL+2 more
IGM Biosciences, Inc. 97
Testing effectiveness (Phase 2)WithdrawnNCT05365100
What this trial is testing

BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL

Who this might be right for
CLL/SLLNHL
BioNova Pharmaceuticals (Shanghai) LTD.
Large-scale testing (Phase 3)WithdrawnNCT00551239
What this trial is testing

Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

Who this might be right for
LeukemiaLymphoma
CTI BioPharma
Very early researchUnknownNCT04639739
What this trial is testing

Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma.

Who this might be right for
NHL
Xinqiao Hospital of Chongqing 9
Testing effectiveness (Phase 2)Looking for participantsNCT05554939
What this trial is testing

Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL

Who this might be right for
Non Hodgkin's Lymphoma
Chinese PLA General Hospital 30
Testing effectiveness (Phase 2)UnknownNCT05896046
What this trial is testing

SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma

Who this might be right for
Relapsed or Refractory Hodgkin Lymphoma
Chinese PLA General Hospital 100
Early research (Phase 1)Ended earlyNCT05965505
What this trial is testing

Study of AXT-1003 in Adult Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas

Who this might be right for
Relapsed or Refractory Non-Hodgkin's Lymphoma
Axter Therapeutics (Beijing) Co., Ltd 1
Early research (Phase 1)UnknownNCT04296461
What this trial is testing

Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma

Who this might be right for
B-cell Non-Hodgkin Lymphoma
UWELL Biopharma 20
Testing effectiveness (Phase 2)Looking for participantsNCT05039073
What this trial is testing

Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors

Who this might be right for
Recurrent Classic Hodgkin LymphomaRefractory Classic Hodgkin Lymphoma
Emory University 46
Not applicableStudy completedNCT00053157
What this trial is testing

Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia

Who this might be right for
Chronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemia+3 more
Roswell Park Cancer Institute 10
Testing effectiveness (Phase 2)Study completedNCT01739309
What this trial is testing

Study of LY2835219 for Mantle Cell Lymphoma

Who this might be right for
Mantle Cell Lymphoma
Eli Lilly and Company 28
Testing effectiveness (Phase 2)Looking for participantsNCT06925464
What this trial is testing

CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas

Who this might be right for
T-Cell Non-Hodgkin LymphomaT-cell Lymphoma (PTCL and CTCL)
Beijing GoBroad Hospital 36
Early research (Phase 1)Study completedNCT00990587
What this trial is testing

Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy

Who this might be right for
Hematologic MalignancyAcute Lymphocytic LeukemiaChronic Lymphocytic Leukemia+4 more
University Health Network, Toronto 20
Early research (Phase 1)Looking for participantsNCT06191887
What this trial is testing

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Who this might be right for
B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell Lymphoma+12 more
Mayo Clinic 27
Large-scale testing (Phase 3)Ended earlyNCT03138499
What this trial is testing

Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,

Who this might be right for
Hodgkin's Disease
Bristol-Myers Squibb 23
Testing effectiveness (Phase 2)Looking for participantsNCT04496349
What this trial is testing

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL

Who this might be right for
T-Prolymphocytic LeukemiaNon-Hodgkins Lymphoma
Ascentage Pharma Group Inc. 78
Testing effectiveness (Phase 2)Ended earlyNCT00079443
What this trial is testing

FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Recurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Small Lymphocytic Lymphoma
National Cancer Institute (NCI) 60
Next Page